The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
The restructured biotech’s new lead project enters phase 1.
A new first-line maintenance phase 3 joins a relapsed pivotal phase 2 study.
But neladalkib results worsen, and come with a red flag about liver enzyme elevations.
The company will imminently start its third pivotal trial of PF-08634404.
The company ditches lorigerlimab in prostate cancer.
But the Day One deal is still 29% below where the shares stood at the start of this year.
